glp-1 obesity drug news updates What is the pipeline for future medications for obesity? Market Overview: GLP-1 Agonists and

Read more about the new GLP-1 pill that outperformed oral semaglutide in a recent Phase III trial.

They see it's $29.99 instead of $1,000

You may have been reading a lot about newly launched obesity drugs and I covered some of this in my podcast last year with Stephan Guyenet in anticipation

Discover how GLP-1 medications are reshaping the food and beverage industry, driving demand for smaller-portion, nutrient-dense products

This article examines clinical evidence for combination therapy, safety profiles, and how genetic predispositions in GLP-1 and glucose metabolism pathways may info

Discussing Pfizer's savvy acquisition of Metsera and critiquing the GLP-1 'gap analysis' many outsiders promote as a reason all the Big Pharmas will be in GLP-1